Pneumocystis Jirovecii Pneumonia in Non-HIV Patients: Insights from a 5-Year UK Retrospective Analysis
Imagine this: a once-rare lung infection, historically tied to the AIDS crisis, is now quietly surging among everyday people battling other health challenges. This isn't just a medical curiosity – it's a growing concern that demands our attention, especially as more individuals live with conditions that weaken their immune defenses. But here's where it gets intriguing: while we've long associated this with HIV, the rise in non-HIV cases is flipping the script, forcing doctors to rethink who needs protection. And this is the part most people miss – the infection's spread into groups like those with arthritis or cancer treatments isn't accidental, but tied to modern medicine itself. Let's dive in and unpack this vital topic, making it accessible even for those new to the world of infectious diseases.
Key Highlights
- We're seeing an upward trend in cases of Pneumocystis jirovecii pneumonia (PCP) among individuals without HIV, whether they have cancer or not.
- People dealing with rheumatological and autoimmune conditions are facing an increasing risk of contracting PCP.
- Considering prophylactic measures against PCP is advisable for high-risk individuals undergoing prolonged immunomodulating treatments.
Getting Started: Understanding the Basics of PCP
Pneumocystis jirovecii pneumonia, often abbreviated as PCP, is a fungal infection that preys on those with compromised immune systems. It's caused by the fungus Pneumocystis jirovecii – formerly known as Pneumocystis carinii – which normally lives harmlessly in our respiratory tracts as a commensal organism. For beginners, think of it like an opportunistic guest at a party who only causes trouble when the host is too weak to keep things in check. PCP typically strikes immunocompromised folks, including HIV patients, those with blood cancers, transplant recipients, and anyone on chronic immunosuppressive drugs.1
In the UK, particularly England, the number of hospital admissions for PCP has climbed steadily. Back in 2012/2013, it stood at 2.2 cases per 100,000 people annually, but by 2021/2022, that figure had risen to 3.9 per 100,000.1 This isn't unique to the UK; a German study by Kolbrink B and colleagues also noted a similar uptick, from 2.3 per 100,000 in 2014 to 2.6 per 100,000 in 2019.2 Traditionally, PCP was almost synonymous with HIV/AIDS, but thanks to effective prophylaxis and antiretroviral therapies, its occurrence and death rates in that group have dropped dramatically.3 The current surge, however, points to a larger pool of vulnerable non-HIV patients, fueled by an aging population, more diagnoses of autoimmune disorders and cancers, and the widespread use of immunosuppressive drugs like B cell-depleting agents.1 To put this in perspective, consider a 2022 report by Scott et al., which found a 42.5% rise in rheumatoid arthritis prevalence in England from 2004 to 2020.4 This spike has led to greater reliance on biologics and disease-modifying treatments, creating long-term immunosuppression that ramps up the risk of infections like PCP.5
A comprehensive meta-analysis on mortality risk factors in non-HIV PCP patients revealed that blood cancers dominate, accounting for 29.1% of cases, trailed by autoimmune diseases (20.1%, especially systemic lupus erythematosus and rheumatoid arthritis), organ or bone marrow transplants (14.0%), and solid tumors (6.0%).6 Most affected individuals had histories of immunosuppressive therapies, such as steroids alone or combined with chemotherapy.6 PCP is no minor threat; fatality rates in non-HIV patients range from 30.6% to 84.2%, underscoring its severity.6-8 With autoimmune and rheumatological diseases driving the trend, the European Alliance of Associations for Rheumatology (EULAR) advises PCP prophylaxis for those on daily prednisolone doses of 15–30 mg or equivalent for 2–4 weeks.9
In their research, the authors explored patient profiles with PCP diagnoses over five years at their hospital, aiming to confirm established risk factors.
How the Study Was Conducted
This was a retrospective, observational, descriptive study focusing on adult PCP patients from January 2019 to December 2023 at a UK District General Hospital. Researchers pulled electronic records using the ICD-10 code B59 for PCP diagnoses.
A PCP case was defined by clinical symptoms, imaging results, microbiological evidence, or a mix of these. They performed descriptive stats, comparing two groups: cancer patients and non-cancer patients, with cancer cases subdivided into blood-related malignancies and others. Analysis used Stata 19 software.
The study received approval from the hospital's Clinical Audit and Research Department and didn't require informed consent, as it was retrospective and didn't involve individual data reporting.
Findings from the Research
Over five years, 33 patients were diagnosed with PCP. Most were male (55%), with an average age of 62.85 years (standard deviation: 13.80). Survivors were notably younger than those who passed away in hospital (one-tailed p=0.03 via two-sample t-test; see Table 1). The top symptom was shortness of breath (67%), followed by fever (33%).
The majority (55%) had no cancer history (Table 1). Of those with neoplasia, 71% had solid tumors and 29% had blood cancers. Solid tumor patients comprised 33% of the total, while blood cancer patients made up 15%.
In non-cancer patients, autoimmune/rheumatological issues were most common (83%), ahead of COPD (61%), diabetes (33%), solid organ transplants (11%), and hepatitis C (6%; Figure 1). Many without cancer were on disease-modifying anti-rheumatic drugs and steroids.
Chest X-rays were the go-to imaging (91%), with 70% showing fresh abnormalities. Only 48% got non-contrast or high-resolution CT scans, all abnormal. CT findings varied widely, including bilateral reticular interstitial opacities, diffuse ground-glass patches, pleural effusions, mosaic interstitial changes, upper lobe thickening, atelectasis, and ground-glass nodules.
Seventy-six percent (19 out of 25) had procalcitonin (PCT) levels below 0.5 ng/mL (Table 1). β-D-glucan (BDG) tested positive (≥80 pg/mL) in 45% (9 out of 20), with no mortality difference between positive and negative groups. Similarly, PCT levels didn't predict death. Patients who died had higher white blood cell and neutrophil counts, but multivariate regression (adjusting for age and conditions) erased this significance.
Sputum induction was done in 18%, with 50% showing P. jirovecii DNA. Bronchoscopy with bronchoalveolar lavage (BAL) occurred in 39%, detecting the pathogen in 85%. Forty-two percent had neither procedure.
Microbiological confirmation via sputum or BAL happened in 42%. Thus, 58% were diagnosed based on clinical or radiological clues. All received high-dose cotrimoxazole for 21 days (unless they died earlier) plus adjunctive prednisolone.
In-hospital death rate was 27%. It was higher in non-cancer patients (39%) than cancer patients (13%), but not statistically significant (one-tailed p=0.105 via Fisher’s exact test; Table 1).
Delving Deeper: What This Means
PCP, once infamous for AIDS patients,10 is now on the rise among those with cancers, autoimmune disorders, and other long-term immunosuppressive needs, like COPD.11
In this study, PCP was more frequent in non-cancer patients (55%), primarily those with autoimmune/rheumatological conditions, COPD, or diabetes (Figure 1). This aligns with broader trends in non-HIV PCP. For instance, Matsumura et al.'s retrospective review of 82 non-HIV PCP cases found 61% had inflammatory diseases like rheumatoid arthritis, lupus, vasculitis, or myopathy, while 21% had solid tumors, 15% blood cancers, and 22% other lung issues.12 Lécuyer et al.'s multicentre study reported 18.1% with immune-mediated inflammation and 21% with COPD.13 A 2-year ICU cohort noted 42% (66 out of 158) had solid or blood tumors.14 This mirrors the authors' 45% malignancy rate, though PCP was more common in non-cancer groups here.
The gold-standard PCP diagnosis involves detecting the fungus in deep respiratory samples via sputum induction or BAL.15 Yet, this was rarely done here, possibly due to challenges in severely ill non-HIV patients.16,17 Among those who had it, most tests were positive.
Given diagnostic hurdles, biochemical markers like BDG are useful.15 In this study, 45% had elevated BDG. Compare that to Iikuni et al., where 78% of 18 PCR-confirmed non-HIV patients had high BDG.18 BDG's link to mortality is debatable;12,18-20 no difference here, possibly because it reflects fungal load, not severity.21 More research is needed on BDG's role in non-HIV PCP.
PCT might also help. Most here had low PCT (<0.5 ng/mL in 19/25), with no mortality tie. In HIV patients, studies like Nyamande et al. show lower PCT in PCP vs. bacterial pneumonia.22 Zeglen et al. linked PCT to PCP colonization in lung transplants.23 But Salerno et al. found no difference in HIV groups, possibly due to unmeasured bacteria.24 We need more on PCT in non-HIV cases.
PCP fatality remains high. HIV patients often recover faster with therapy, but non-HIV immunosuppression, like steroids, may worsen inflammation with heavy fungal burdens.25 The 27% rate here is lower than 30.6–84.2% in other reports.6-8 Non-cancer patients died more (39% vs. 13% in cancer), though not significantly (p=0.105). Kamel et al.'s French study showed higher deaths in non-cancer groups (40.8% in 'others' like autoimmune patients) compared to cancers (37.9%), with significant differences (p=0.005).14
Univariate analysis linked older age, high white cells, and neutrophils to death (Table 1), but multivariate adjustment nullified this. Meta-analyses cite age, pulmonary issues, tumors, cytomegalovirus, lactate dehydrogenase, lymphocyte counts, ventilation, and pneumothorax as predictors.26
PCP risks stem from immune deficits and immunosuppressants, especially steroids.27-29 The shifting non-HIV epidemiology highlights prophylaxis needs. Routine prophylaxis in cancer and transplant patients explains why rheumatological cases stand out. Matsumura Y et al. found two-thirds had inflammatory diseases, fewer malignancies or transplants.12 EULAR recommends prophylaxis for autoimmune rheumatic patients on high glucocorticoids, noting limited evidence.9 They urge better risk tools factoring age, comorbidities, and specifics for tailored prevention, balancing benefits against overuse. Common prophylaxis: trimethoprim-sulfamethoxazole (480 mg daily or 960 mg thrice weekly).
Challenges and Caveats
As a retrospective study, limitations abound. The small sample (33 patients) limits conclusions and statistical power on disease-mortality links, though descriptive insights are valuable.
ICD coding might undercount cases if misassigned.
Lack of immunosuppressive details (regimens, durations) could skew outcomes, constrained by record access. Uncaptured factors like nutrition, smoking, or disease severity add confounders.
Diagnostic inconsistency is key; over half lacked organism confirmation, mirroring real-world hurdles.
Wrapping It Up
This study underscores PCP's rise in non-HIV patients, driven by immunosuppressive treatments for autoimmune/rheumatological issues and cancer care. Fatality stays high, so clinicians should suspect PCP in vulnerable groups like rheumatology patients, cancer survivors, or those on long-term immunosuppressants. Robust risk tools are essential for evolving at-risk populations.
But here's the controversial twist: Is routine prophylaxis for everyone on steroids overkill, or a necessary shield against this deadly fungus? And this is the part that sparks debate – with evidence mixed on biomarkers like BDG and PCT, should we push for more invasive diagnostics, even if it means discomfort for patients? What are your thoughts? Do you agree prophylaxis should expand beyond transplants and cancers to include autoimmune flares? Disagree? Let's hear it in the comments – your perspectives could shape future guidelines!
